1. Home
  2. LQDA vs PBH Comparison

LQDA vs PBH Comparison

Compare LQDA & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$35.14

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc.

HOLD

Current Price

$61.48

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
PBH
Founded
2004
1996
Country
United States
United States
Employees
N/A
600
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
3.0B
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
LQDA
PBH
Price
$35.14
$61.48
Analyst Decision
Strong Buy
Buy
Analyst Count
10
5
Target Price
$37.40
$86.40
AVG Volume (30 Days)
1.7M
439.1K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
4.04
Revenue
$69,216,000.00
$1,110,479,000.00
Revenue This Year
$904.79
N/A
Revenue Next Year
$188.25
$2.50
P/E Ratio
N/A
$15.20
Revenue Growth
343.41
N/A
52 Week Low
$10.37
$57.25
52 Week High
$35.54
$90.04

Technical Indicators

Market Signals
Indicator
LQDA
PBH
Relative Strength Index (RSI) 67.11 56.46
Support Level $32.11 $59.52
Resistance Level $35.54 $62.40
Average True Range (ATR) 1.50 1.44
MACD -0.05 0.32
Stochastic Oscillator 92.26 79.01

Price Performance

Historical Comparison
LQDA
PBH

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Share on Social Networks: